510(k) Report

510(k) · Cleared

Cleared

Access AMH

K170524510(k) TraditionalCleared Nov 13, 2017264-day reviewClass II21 CFR 862.1092

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Beckman Coulter, Inc. · PQO Anti-Müllerian Hormone Test System

Cleared on Nov 13, 2017 as substantially equivalent to DEN150057 (Roche Diagnostics, 2016) after a 264-day review. Its family tree reaches back 1 generation to 2016. 2 later devices descend from it.

Decided
Nov 13, 2017
Review
264 days
Class
Class II
Product code
PQO
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to DEN150057 (2016). 2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2023: 2 descendants clearedDEN150057 · Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5 · Roche Diagnostics · 2016201620182020202220242026
Descendants, by generation 1 generation forward: 2 descendants DEN150057 · Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5 · Roche Diagnostics · 20160
  1. Root · 1 generation backDEN150057 Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5Roche Diagnostics · 2016
  2. This deviceK170524 Access AMHBeckman Coulter, Inc. · 2017
  3. Descendant · cites it directly · 0 of its ownK221801 ADVIA Centaur® Anti-Müllerian Hormone (AMH)Siemens Healthcare Diagnostics, Inc. · 2023
  4. Descendant · cites it directly · 0 of its ownK223679 Access AMHBeckman Coulter, Inc. · 2023

Most influential descendants

Showing 2 of 2 · See all
  • K221801ADVIA Centaur® Anti-Müllerian Hormone (AMH)Siemens Healthcare Diagnostics, Inc. · 2023 · cites it directly0descendants
  • K223679Access AMHBeckman Coulter, Inc. · 2023 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1DEN150057Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5Roche Diagnostics2016—
0 (this device)K170524Access AMHBeckman Coulter, Inc.2017—
+1K221801ADVIA Centaur® Anti-Müllerian Hormone (AMH)Siemens Healthcare Diagnostics, Inc.2023—
+1K223679Access AMHBeckman Coulter, Inc.2023—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202320
FIG. 1 — Lineage of K170524, 2016–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PQO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PQO device

  1. #1 K221801 ADVIA Centaur® Anti-Müllerian Hormone (AMH)score 5.7 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*DEN150057Elecsys AMH, AMH CalSet, PreciControl AMH, AMH CalCheck 5
Summary page 5
…m Classification Name: Anti-Müllerian hormone test system Product Code PQO (21 CFR 862.1092) Predicate Device Roche Elecsys® AMH System (DEN150057) Manufactured by Roche Diagnostics GmbH Beckman Coulter Inc. Access AMH Assay Traditional 510(k) Page 1 of 11 === Page…
Roche Diagnostics2016—

Also cleared against DEN150057: 1 other device →

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K221801ADVIA Centaur® Anti-Müllerian Hormone (AMH)Siemens Healthcare Diagnostics, Inc.20230
K223679Access AMHBeckman Coulter, Inc.20230

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • Of its descendants, K221801 (Siemens Healthcare Diagnostics, Inc., 2023) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate DEN150057.

How does its category compare?

All PQO devices

PQO Anti-Müllerian Hormone Test System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2017, this device’s year, is highlighted.

FDA decisions per year · PQO

2in 2023

2016: 12017: 12022: 12023: 2
2007high 2 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PQO

Too few PQO 510(k)s in any year since 2007 to give a median.

Recalls per year · PQO

1in 2025

2025: 1
2007high 1 (2025) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PQO

1in 2025

2017: 22018: 22019: 42020: 12022: 22023: 12024: 12025: 1
2007high 4 (2019) · low 0 (2007)2025

MAUDE reports naming product code PQO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20161—00
20171—02
20180—02
20190—04
20200—01
20210—00
20221—02
20232—01
20240—01
20250—11
20260—0—

What is it indicated for?

The Access AMH assay is a paramagnetic particle chemiluminescent immunoassay for the quantitative determination of anti-Müllerian hormone (AMH) levels in human serum and lithium heparin plasma using the Access Immunoassay Systems as an aid in the assessment of ovarian reserve in women presenting to fertility clinics. This system is intended to distinguish between women presenting with AFC (antral follicle count) values > 15 (high ovarian reserve) and…

Read the full statement (126 words)

The Access AMH assay is a paramagnetic particle chemiluminescent immunoassay for the quantitative determination of anti-Müllerian hormone (AMH) levels in human serum and lithium heparin plasma using the Access Immunoassay Systems as an aid in the assessment of ovarian reserve in women presenting to fertility clinics. This system is intended to distinguish between women presenting with AFC (antral follicle count) values > 15 (high ovarian reserve) and women with AFC values ≤ 15 (normal or diminished ovarian reserve). The Access AMH is intended to be used in conjunction with other clinical and laboratory findings such as antral follicle count, before starting fertility therapy. The Access AMH is not intended to be used for monitoring of women undergoing controlled ovarian stimulation in an Assisted Reproduction Technology program.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K170524: Access AMH.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K170524

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026